Research and possible future brain health treatments

Size: px
Start display at page:

Download "Research and possible future brain health treatments"

Transcription

1 Research and possible future brain health treatments Cheryl Brandi, DNSc, ARNP, NP-C Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 1

2 The Roskamp Institute Not for profit biomedical research institute and clinic > 60 staff including Ph.D. scientists, clinicians, Ph.D. students, research associates, technicians, administrative staff and consultants Research targets neurological and neuropsychiatric disorders Funding: National Institutes of Health; Veterans Administration; Department of Defense; Alzheimer s Association; Roskamp Foundation; Pharma; Publicprivate partnerships; Private donations 2

3 Roskamp Institute Programs Roskamp Laboratories Archer Pharmaceuticals - Nilvadipine SRQ Bio Contract Research Roskamp Clinic Neurology clinic Clinical trials Mild Cognitive Impairment, Alzheimer s, Multiple Sclerosis, Migraine, etc. 3

4 Understanding brain health and dementia July 21, 2016 brandi, roskamp institute 4

5 What should I believe? July 21, 2016 brandi, roskamp institute 5

6 The continuum of neurocognitive disease research 3. Treatment of disease and finding a cure 2. Earlier and more accurate diagnosing 1. Prevention, risk factor identification and risk factor modification*** What is the current state of science? July 21, 2016 brandi, roskamp institute 6

7 3. Treatment of disease, finding a cure; Alzheimer s disease Currently only 5 FDA approved drugs 4 drugs came to market between 1996 and 2003 Last drug was approved in 2014, but is a combination of two older drugs No approved drugs work at the disease targets proteins such as amyloid and tau July 21, 2016 brandi, roskamp institute 7

8 Amyloid plaques in brain tissue July 21, 2016 brandi, roskamp institute 8

9 Why has drug development been so slow? Stigma, denial Money Lack of volunteers needed for clinical trials July 21, 2016 brandi, roskamp institute 9

10 Money: Federal funding in billion to cancer 1.2 billion to heart disease 3 billion to HIV/AIDS Only 566 million to Alzheimer s Disease July 21, 2016 brandi, roskamp institute 10

11 Volunteers 70,000 volunteers urgently needed for 150 clinical trials and research studies in the U.S. related to Alzheimer s Disease (National Institute of Aging 2015) July 21, 2016 brandi, roskamp institute 11

12 Clinical trials offer hope for our future Clinical trials are a way to learn if a treatment is effective and safe Most involve drugs and a placebo Very strict laws govern the way clinical trials are conducted July 21, 2016 brandi, roskamp institute 12

13 So Promising advances in Alzheimer s disease treatment Experimental drugs that target specific disease proteins such as beta amyloid, tau, beta secretase Trials ongoing at Roskamp Institute Different uses for older drugs nilvadipine An encouraging Roskamp Institute trial in Europe (NILVAD) July 21, 2016 brandi, roskamp institute 15

14 Nilvadipine, an older drug with a promising new role A blood pressure medication used in Europe Nilvadipine in animal studies was shown to block production of amyloid and increase cortical brain circulation in animal models Phase 3 trials are nearing completion from 9 sites throughout Europe (NILVAD) Data will soon be analyzed, results finalized STAY TUNED!! July 21, 2016 brandi, roskamp institute 16

15 2. Earlier and more accurate diagnosing New imaging techniques an ability to see amyloid buildup on MRI to aid diagnosis IDEAS trial across the US, Roskamp Institute participates Better understanding of Mild Cognitive Impairment Biomarker validation for earlier detection Current study at Roskamp Institute Clinic July 21, 2016 brandi, roskamp institute 17

16 1. Prevention and risk factor modification In the absence of disease modifying treatments, risk reduction takes on new meaning Even with new treatments, risk reduction will be a basic strategy Clinical studies are limited regarding specific interventions, but evidence is sufficient to support modifiable risk factors (Baumgart et el: Summary of the evidence on modifiable risk factors..alzheimer s and Dementia 11(2015) ) July 21, 2016 brandi, roskamp institute 18

17 Risk factors Cannot change age, family history and genetic susceptibility July 21, 2016 brandi, roskamp institute 19

18 Risk factors There is sufficient evidence to support associations or linkages between modifiable risk factors and reduction in risk for mild cognitive impairment and dementia July 21, 2016 brandi, roskamp institute 20

19 Cardiovascular risk factors July 21, 2016 brandi, roskamp institute 21

20 Cardiovascular risk factors for cognitive decline Diabetes strong evidence on increased risk of dementia in people with diabetes Mid-life obesity strong evidence for an increased risk of dementia Mid-life hypertension strong evidence for an increased risk of Mild Cognitive Impairment July 21, 2016 brandi, roskamp institute 22

21 Lifestyle factors that reduce risk Stop smoking Physical activity even mild activity is linked to decreased risk of cognitive impairment Diet combined Mediterranean/Dash diet probably has most evidence among diets for reducing risk of cognitive decline and dementia July 21, 2016 brandi, roskamp institute 23

22 Other risk factors Education fewer years of education linked to increased risk of dementia Traumatic brain injury solid evidence to link to increased risk of dementia History of depression moderate link to increased risk of cognitive decline Sleep {Caregivers of family members with dementia} July 21, 2016 brandi, roskamp institute 24

23 Summary Research regarding neurocognitive diseases is promising but has a long way to go However, YOU CAN reduce your risk now! July 21, 2016 brandi, roskamp institute 25

24 and in conclusion.. July 21, 2016 brandi, roskamp institute 26

25 Roskamp Institute Roskamp Institute 2040 Whitfield Ave. Sarasota, FL Phone: Roskamp Institute Clinic Phone: July 21, 2016 brandi, roskamp institute 27

PUBLIC POLICIES AND ALZHEIMER RESEARCH

PUBLIC POLICIES AND ALZHEIMER RESEARCH PUBLIC POLICIES AND ALZHEIMER RESEARCH 25TH ALHEIMER EUROPE CONFERENCE SEPTEMBER 2015 INTRODUCTION France Alzheimer and related diseases has, since its creation, put research at the center of its priorities

More information

Alzheimer s Disease Update: From Treatment to Prevention

Alzheimer s Disease Update: From Treatment to Prevention Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science

More information

Understanding Symptoms, Causes, and Risks for Alzheimer s Disease

Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging

More information

BGS Spring Risk Factors and Preventative Strategies for Dementia

BGS Spring Risk Factors and Preventative Strategies for Dementia Risk Factors and Preventative Strategies for Dementia Dr Blossom Stephan Senior Lecturer (in Risk Prediction) Newcastle University Institute for Ageing and Institute of Health and Society BGS Spring Meeting

More information

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS.

The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. HEALTH FACTS The ALS Association Mid-America Chapter 87 people in Nebraska have ALS. Every 90 minutes, someone is diagnosed with or passes away from ALS. Alzheimer s Association Nebraska Chapter 5.5 million

More information

Fact Sheet Alzheimer s disease

Fact Sheet Alzheimer s disease What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,

More information

11/5/2018. Alzheimer s Disease Working Group: An Update. Learning Objectives. Facts & Figures

11/5/2018. Alzheimer s Disease Working Group: An Update. Learning Objectives. Facts & Figures Alzheimer s Disease Working Group: An Update Learning Objectives Learn why early detection, diagnosis, and connections to resources are important. Understand the key recommendations from the 2011 Alzheimer

More information

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018 Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been

More information

Dementia prevention in the 21 st century

Dementia prevention in the 21 st century Dementia prevention in the 21 st century Stina Saunders, MRes 10 th Scottish Caring & Dementia Congress April 2018 Dementia rates In the UK, one person every three minutes develops dementia that is 1 in

More information

years Towards a world without dementia

years Towards a world without dementia years 1 9 0 6-2 0 0 6 Towards a world without dementia A message from our patron A rewarding part of my public life has been my association with Alzheimer s Australia. During the National Consumer Summit

More information

Alzheimer s disease. What is Alzheimer s disease?

Alzheimer s disease. What is Alzheimer s disease? Alzheimer s disease What is Alzheimer s disease? What do we know about dementia and Alzheimer s disease? Alzheimer s disease is the most common form of dementia. Alzheimer s disease causes symptoms of

More information

100 billion neurons!

100 billion neurons! 100 billion neurons! Where s my car parked? Normal Memory Changes with Age Memory changes start even before 30 Harder to store new memories Sensory inputs aren't as sharp hear, see, taste Multi-tasking

More information

Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana

Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Finding Solutions to the Alzheimer s Disease Epidemic in Indiana: Alzheimer s Research in Indiana Bruce Lamb, Ph.D. Executive Director Stark Neurosciences Research Institute September 13, 2017 Critical

More information

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:

More information

Appendix C CHANGING THE TRAJECTORY:

Appendix C CHANGING THE TRAJECTORY: Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario

More information

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There

More information

Improving Dementia Services in Northern Ireland. A Regional Strategy

Improving Dementia Services in Northern Ireland. A Regional Strategy Improving Dementia Services in Northern Ireland A Regional Strategy Contents 01. Introduction 02. Helpful words 04. About the strategy 05. Why dementia is an important condition 06. The impact of dementia

More information

Alzheimer s Disease Research

Alzheimer s Disease Research PRA INSIGHTS REPORT Alzheimer s Disease Research JULY 2017 Page 01 of 9 TABLE OF CONTENTS Introduction Methodology Summary Question One: Demographics Question Two: The Foremost Challenge in Neuroscience

More information

FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018

FROM THE ALZHEIMER S ASSOCIATION INTERNATIONAL CONFERENCE 2018 FOR IMMEDIATE RELEASE CONTACT: Alzheimer s Association AAIC Press Office, 312-949-8710, aaicmedia@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, nfrantz@alz.org FROM THE ALZHEIMER S ASSOCIATION

More information

What is dementia. with Lewy bodies?

What is dementia. with Lewy bodies? What is dementia with Lewy bodies? Contents 03 What is dementia with Lewy bodies? 04 Symptoms 05 Diagnosis 06 Treatments Information in this booklet is for anyone who wants to know more about dementia

More information

MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH

MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH Nicci Kobritz, President Center for Brain Health & Youthful Aging Home Health 1 Our Goal Reduce the impact of modifiable medical risk factors associated

More information

Alzheimer s disease is an

Alzheimer s disease is an Alzheimer s Disease FACT SHEET Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest

More information

Diabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian

Diabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes

More information

Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy

Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy 1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation

More information

2018 Candidate Guide. Leading in the fight to end Alzheimer's

2018 Candidate Guide. Leading in the fight to end Alzheimer's 2018 Candidate Guide Leading in the fight to end Alzheimer's Table of Contents Candidate Letter...2 2018 Alzheimer's Disease Facts and Figures...3 Federal Policies to Lead on Alzheimer's...4 State Policies

More information

Parkinson s Research Program

Parkinson s Research Program Parkinson s Research Program Strategic Plan INTRODUCTION The Congressionally Directed Medical Research Programs (CDMRP) represents a unique partnership among the U.S. Congress, the military, and the public

More information

Prioritizing Disease Prevention. Man and women, young and old, black and white, gay and straight, rich and poor,

Prioritizing Disease Prevention. Man and women, young and old, black and white, gay and straight, rich and poor, El-Magbri 1 Prioritizing Disease Prevention Man and women, young and old, black and white, gay and straight, rich and poor, all are susceptible. Over 35 million are inflicted and the lives of far too many

More information

CAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA?

CAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA? CAMPAIGN BRIEF: WHY DO WE NEED ACTION ON DEMENTIA? Changes in Government Policy The Government has terminated the Dementia Initiative and risks squandering 6 years of investment. The Dementia Initiative

More information

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT

SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT SUPPORT FEDERAL FUNDING FOR PARKINSON S DISEASE RESEARCH AND DRUG DEVELOPMENT Parkinson s disease (PD) affects an estimated 750,000 to 1 million Americans. Currently, there is no treatment to slow, stop

More information

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health. Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:

More information

The Aging Brain The Aging Brain

The Aging Brain The Aging Brain The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu

More information

Mentis Cura November

Mentis Cura November Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million

More information

Peer Reviewed Alzheimer s Research Program (PRARP)

Peer Reviewed Alzheimer s Research Program (PRARP) Peer Reviewed Alzheimer s Research Program (PRARP) Col Wanda L. Salzer, USAF Director, CDMRP Anthony Pacifico, Ph.D. Program Manager, PRARP Disclaimer The information in this presentation is the opinion

More information

Investor Update. Downloads. Services PDF. Basel, 17 July 2017

Investor Update. Downloads. Services PDF. Basel, 17 July 2017 Investor Update Basel, 17 July 2017 Roche s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and

More information

Assessing and Managing the Patient with Cognitive Decline

Assessing and Managing the Patient with Cognitive Decline Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor

More information

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?

Alzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD? 2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),

More information

Strategies for Dementia and Alzheimer s Care. Welcome and Introduction. Thank you, Why this topic? 3/9/2017

Strategies for Dementia and Alzheimer s Care. Welcome and Introduction. Thank you, Why this topic? 3/9/2017 Strategies for Dementia and Alzheimer s Care LEADERS 2017 SLIDES PREPARED FOR PREVIEW MARCH CAMILLE PAVY CLAIBOURNE, APRN, PHD. Welcome and Introduction STRATEGIES CARING AND COMMUNICATING IN CAREGIVING

More information

CEO Operational Report. Annual General Meeting 23 October 2013

CEO Operational Report. Annual General Meeting 23 October 2013 CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting

More information

First US Plan to Address Alzheimer s Disease

First US Plan to Address Alzheimer s Disease First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory

More information

Molecular Imaging and the Brain

Molecular Imaging and the Brain Molecular imaging technologies are playing an important role in neuroimaging, a branch of medical imaging, by providing a window into the living brain. Where CT and conventional MR imaging provide important

More information

ALZHEIMER S ASSOCIATION

ALZHEIMER S ASSOCIATION ALZHEIMER S ASSOCIATION Our mission: To eliminate Alzheimer s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through

More information

There For You. Your Compassionate Guide. World-Class Hospice Care Since 1979

There For You. Your Compassionate Guide. World-Class Hospice Care Since 1979 There For You Your Compassionate Guide World-Class Hospice Care Since 1979 What Is Hospice? Hospice is a type of care designed to provide support during an advanced illness. Hospice care focuses on comfort

More information

Vascular and Degenerative Causes of Cognitive Impairment: How are they linked?

Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? MCI Symposium, Public Education Forum Presented by: Rebecca Gottesman, MD PhD January 20, 2019 1 Disclosures I am an Associate

More information

Understanding Clinical Trials

Understanding Clinical Trials An excerpt from: Understanding Clinical Trials What is a clinical trial? Although there are many definitions of clinical trials, they are generally considered to be biomedical or health-related research

More information

Working with Your. Neurologist

Working with Your. Neurologist Working with Your Neurologist What Is a Neurologist? A neurologist is a medical doctor with specialized training in diagnosing, treating, and managing disorders of the brain and nervous system. Neurologists

More information

Shaping the Future of Dementia Care. Cheryl Miller, Phoebe Ministries Staff Development Coordinator

Shaping the Future of Dementia Care. Cheryl Miller, Phoebe Ministries Staff Development Coordinator Shaping the Future of Dementia Care Cheryl Miller, Phoebe Ministries Staff Development Coordinator Objectives By the end of this session attendees will be able to: 1. List three modifiable risk factors

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. ALS (Amyotrophic Lateral Sclerosis) Approximately 95 people in Nebraska have ALS. As many as 800 Nebraskans

More information

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future

DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY

More information

CHRONIC CONDITIONS FYI

CHRONIC CONDITIONS FYI CHRONIC CONDITIONS FYI AIDS More than 2,500 cases of HIV/AIDS have been identified in Nebraska. Nationwide, this number is more than 1.2 million. ALS (Amyotrophic Lateral Sclerosis) There are 87 people

More information

Peer Reviewed Alzheimer s Research Program

Peer Reviewed Alzheimer s Research Program Peer Reviewed Alzheimer s Research Program US Army Medical Research and Materiel Command Congressionally Directed Medical Research Programs HISTORY The Congressionally Directed Medical Research Programs

More information

2017 ALZHEIMER'S DISEASE FACTS AND FIGURES

2017 ALZHEIMER'S DISEASE FACTS AND FIGURES Page 1 of 5 2017 ALZHEIMER'S DISEASE FACTS AND FIGURES By Diana Iuliano-Chan, Region IV NARFE-Alzheimer's Regional Coordinator. The number of Americans living with Alzheimer's disease is growing and growing

More information

New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International Conference

New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International Conference Media Contacts: David Patti JFK Communications dpatti@jfkhealth.com (609) 241-7365 New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International

More information

Research ALZHEIMER S DISEASE AND RISK FACTORS

Research ALZHEIMER S DISEASE AND RISK FACTORS Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the

More information

ALZHEIMER'S DISEASE PREVENTION TRIALS

ALZHEIMER'S DISEASE PREVENTION TRIALS ALZHEIMER'S DISEASE PREVENTION TRIALS Laurie Ryan, PhD Chief, Dementias of Aging Branch & Program Director, Alzheimer s Disease Clinical Trials Division of Neuroscience National Institute on Aging/National

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

Medical and scientific advances in prevention and treatment of dementia

Medical and scientific advances in prevention and treatment of dementia Medical and scientific advances in prevention and treatment of dementia 12 th UK Dementia Congress Doncaster Prof Craig Ritchie Centre for Dementia Prevention Centre for Clinical Brain Sciences University

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

CARE CAMPUS EIT Health Hearing. CARE CAMPUS Caring and Ageing Reimagined in Europe. October 11 th, 2017

CARE CAMPUS EIT Health Hearing. CARE CAMPUS Caring and Ageing Reimagined in Europe. October 11 th, 2017 EIT Health Hearing Caring and Ageing Reimagined in Europe October 11 th, 2017 MISSION EIT Health accelerate entrepreneurship and innovation in healthy living and active ageing. Population Ageing is a global

More information

Dietary Supplements, Caffeine, and Cognitive Aging

Dietary Supplements, Caffeine, and Cognitive Aging Institute of Medicine Committee on the Public Health Dimensions of the National Academies Beckman Center of the National Academies Irvine, CA June 9, 2014 Dietary Supplements, Caffeine, and Cognitive Aging

More information

Restoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected.

Restoration. JDRF is turning Type One into Type None. attack so the newly restored beta cell function is protected. Restoration JDRF is turning Type One into Type None Type 1 diabetes (T1D) is an extraordinarily complex disease. Finding the cure a short-term clinical intervention, with minimal side effects, after which

More information

UNDERSTANDING ALZHEIMER S AND DEMENTIA

UNDERSTANDING ALZHEIMER S AND DEMENTIA UNDERSTANDING ALZHEIMER S AND DEMENTIA Geri T., living with Alzheimer's, and her husband and care partner, Jim T. THE IMPACT OF ALZHEIMER S AND DEMENTIA Currently, an estimated 50 million people worldwide

More information

Understanding. Alzheimer s Disease. Lora, diagnosed in 2004, with her daughter, Jill.

Understanding. Alzheimer s Disease. Lora, diagnosed in 2004, with her daughter, Jill. Understanding Alzheimer s Disease Lora, diagnosed in 2004, with her daughter, Jill. What Is Alzheimer s Disease? Alzheimer s disease is a neurologic disorder that affects the brain. It causes dementia.

More information

Featured Topic: Alzheimer s (5 slides)

Featured Topic: Alzheimer s (5 slides) Featured Topic: Alzheimer s (5 slides) The Rise of Alzheimer s Disease Mild memory problem: where did I put my car keys? Alzheimer s: what am I supposed to do with these keys? Scary Statistics: Between

More information

UCLA Alzheimer s and Dementia Care: Comprehensive, Coordinated, Patient-Centered

UCLA Alzheimer s and Dementia Care: Comprehensive, Coordinated, Patient-Centered UCLA Alzheimer s and Dementia Care: Comprehensive, Coordinated, Patient-Centered David Geffen School of Medicine at UCLA Director: David B. Reuben, MD Medical Director: Zaldy S. Tan, MD, MPH Lead Dementia

More information

Alzheimer s: Our Next Public Health Success Story. John Shean, MPH Associate Director, Public Health Alzheimer s Association

Alzheimer s: Our Next Public Health Success Story. John Shean, MPH Associate Director, Public Health Alzheimer s Association Alzheimer s: Our Next Public Health Success Story John Shean, MPH Associate Director, Public Health Alzheimer s Association What is Public Health? What is Public Health? People Communities 3 What is Public

More information

Advances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017

Advances in Alzheimer s diagnosis; implications for clinical practice. Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Advances in Alzheimer s diagnosis; implications for clinical practice Wiesje M. van der Flier Alzheimer Europe Conference Berlin, 4 October 2017 Grand Challenge Alzheimer s disease 47 million worldwide

More information

Getting to Know the Generation Program s Approach to Disclosing Information about Your Risk for Alzheimer s disease

Getting to Know the Generation Program s Approach to Disclosing Information about Your Risk for Alzheimer s disease Getting to Know the Generation Program s Approach to Disclosing Information about Your Risk for Alzheimer s disease The Generation Program is made up of two clinical trials: Generation Study 1 and Generation

More information

Sixth Annual Seattle Hope Gala

Sixth Annual Seattle Hope Gala American Cancer Society Sixth Annual Seattle Hope Gala The Facts Event Information The American Cancer Society sixth annual Seattle Hope Gala will be held on Saturday, October 11, 2014, at Fremont Studios

More information

1 in 3 seniors dies with Alzheimer s or another dementia.

1 in 3 seniors dies with Alzheimer s or another dementia. 2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers

More information

SPONSORSHIP OPPORTUNITIES

SPONSORSHIP OPPORTUNITIES SPONSORSHIP OPPORTUNITIES 2018 WHAT IS HYDROCEPHALUS? Hydrocephalus is caused by an imbalance in the production and absorption of cerebral spinal fluid in the brain which causes the ventricles to enlarge.

More information

Building Quality Into Outpatient Dementia Care For Mainers

Building Quality Into Outpatient Dementia Care For Mainers Building Quality Into Outpatient Dementia Care For Mainers Cliff Singer MD Chief, Geriatric Mental Health and Neuropsychiatry Principal Investigator, Alzheimer s Disease Clinical Research Program Acadia

More information

Consultation on Australian Medical Research and Innovation Priorities for

Consultation on Australian Medical Research and Innovation Priorities for Australian Medical Research Advisory Board Consultation on Australian Medical Research and Innovation Priorities for 2018-2021 Submission from Dementia Australia July 2018 1 About Dementia Australia Dementia

More information

Alzheimer s Association: Public Health Perspectives & Initiatives

Alzheimer s Association: Public Health Perspectives & Initiatives Alzheimer s Association: Public Health Perspectives & Initiatives Maria C. Carrillo, Ph.D. Chief Science Officer Disclosures: Full time employee of the Alzheimer s Association 2 Outline Prevalence vs Incidence

More information

Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967

Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967 Comments to the U.S. Food and Drug Administration Regarding the Patient-Focused Drug Development Re: Docket No. FDA-2012-N-0967 The American Lung Association welcomes the opportunity to comment on the

More information

Contents. Introduction. Introduction 03

Contents. Introduction. Introduction 03 Genes and dementia Introduction This information is for anyone who wants to know more about the link between genes and dementia. This includes people living with dementia, their carers, friends and families.

More information

Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease Pennsylvania Avenue NW, Washington, DC June 20, 2017

Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease Pennsylvania Avenue NW, Washington, DC June 20, 2017 Exploring Outcomes and Value across the Spectrum of Alzheimer s Disease 1201 Pennsylvania Avenue NW, Washington, DC 20004 June 20, 2017 Meeting Summary Meeting Objectives Alzheimer s disease (AD) has a

More information

DISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY. Presented by Rob Parke Lalit Baveja

DISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY. Presented by Rob Parke Lalit Baveja DISEASE MANAGEMENT: A CASE FOR COST EFFECTIVENESS AND QUALITY CARE Presented by Rob Parke Lalit Baveja Jaiwardhan Vij February 12-13, 13 2009 Agenda India s s Chronic Disease Burden Overview of Disease

More information

Treatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK

Treatments of tomorrow: dementia research and drug discovery. Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK Treatments of tomorrow: dementia research and drug discovery Dr Matthew Norton Director of Policy and Strategy, Alzheimer s Research UK More failure What is different about dementia drug discovery? The

More information

American Cancer Society

American Cancer Society American Cancer Society Breast Cancer Awareness for the Worksite HAP Worksite Wellness Forum October 18,2012 Melissa DiPirro Coordinator, Health Initiatives Official Sponsor of Birthdays Mission: We are

More information

our vision our mission 7/24/18 Twin Ports Conference Session 202 Learning Objectives

our vision our mission 7/24/18 Twin Ports Conference Session 202 Learning Objectives Twin Ports Conference Session 202 Memory Loss and Dementia: An African American and Health Euity Lens Alzheimer s Association: Robbin Frazier, Director of Diversity and Inclusion E-mail: rfrazier@alz.org

More information

Dementia and cognitive decline

Dementia and cognitive decline Dementia and cognitive decline Expert Briefing Su Ray and Dr Susan Davidson Research Department Together, we can help everyone to love later life 01 Brain basics Normal ageing, cognitive impairment and

More information

Alzheimer s disease Dispelling the myths

Alzheimer s disease Dispelling the myths Alzheimer s disease Dispelling the myths Myth and Reality Over the years, many myths have evolved about what Alzheimer s disease is, who gets it and how it affects people who have it. These myths can add

More information

Chronic Effects of Neurotrauma Consortium (CENC)

Chronic Effects of Neurotrauma Consortium (CENC) Chronic Effects of Neurotrauma Consortium (CENC) 2013-2019 David X. Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Associate Dean for Innovation and System Integrations, Virginia Commonwealth

More information

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016

Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer

More information

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease

BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in

More information

Ranking Nutritional Supplements Botanical Medicine Primary

Ranking Nutritional Supplements Botanical Medicine Primary Your Monthly Update Dear Colleague Welcome to the October newsletter from Pure Bio Ltd. Did you know...? The UK organic market grew by 30% and averaged sales of 7million a week in 2005! Our topic for this

More information

reverse parkinsons BAD27E3FE044E25F3F8EBDA3B54333A9 Reverse Parkinsons 1 / 6

reverse parkinsons BAD27E3FE044E25F3F8EBDA3B54333A9 Reverse Parkinsons 1 / 6 Reverse Parkinsons 1 / 6 2 / 6 3 / 6 Reverse Parkinsons Reverse Parkinson's Disease!-Take back your life! Do you want to improve your quality of life, when you have Parkinson's disease? Contrary to the

More information

Clinical Research Studies at Johns Hopkins Bayview. Frequently Asked Questions

Clinical Research Studies at Johns Hopkins Bayview. Frequently Asked Questions Clinical Research Studies at Johns Hopkins Bayview Frequently Asked Questions Without clinical research, progress in improving health and treatment of disease would not be possible. To achieve success,

More information

National Plan to Address Alzheimer s Disease

National Plan to Address Alzheimer s Disease National Plan to Address Alzheimer s Disease On May 15, 2012, the Obama Administration released our country s first-ever National Alzheimer s Plan. What is this plan? Why is it needed? And how will it

More information

Your legacy. Their cure. The Brain Tissue Resource Facility

Your legacy. Their cure. The Brain Tissue Resource Facility Your legacy. Their cure. The Brain Tissue Resource Facility Your donation offers future generations the hope of a cure. An introduction to brain tissue donation and the autopsy assistance program One of

More information

2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES

2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES 2018 WALK TO END HYDROCEPHALUS Twin Cities, MN SPONSORSHIP OPPORTUNITIES WHAT IS HYDROCEPHALUS? Hydrocephalus is caused by an imbalance in the production and absorption of cerebral spinal fluid in the

More information

The summit and its purpose

The summit and its purpose Sponsors: 1 The summit and its purpose The Translational Hearing Research Summit: Biological and Pharmacological Approaches was an international summit that gathered 159 delegates, from 14 countries to

More information

MASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER

MASSACHUSETTS ALZHEIMER S DISEASE RESEARCH CENTER MASSACHUSETTS ALZHEIMER S THE NEWSLETTER DISEASE RESEARCH OF THE CENTER Volume 1, Issue 4 Winter 2010 http://madrc.mgh.harvard.edu/ Mild Cognitive Impairment (MCI) A new look at early changes MASSACHUSETTS

More information

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and

More information

The Special Diabetes Program

The Special Diabetes Program The Special Diabetes Program Advancing Research & Improving Lives on the Path to a Cure Charlie was diagnosed with T1D at 10 months old. Some days, he wants to be a doctor when he grows up. Other days,

More information

The REACH Caregiver Intervention Program: From Clinical Trial to Community Implementation. HRJ Endowed Chair University of Michigan

The REACH Caregiver Intervention Program: From Clinical Trial to Community Implementation. HRJ Endowed Chair University of Michigan The REACH Caregiver Intervention Program: From Clinical Trial to Community Implementation Lou Burgio, Ph.D. HRJ Endowed Chair University of Michigan Background dementia (Facts and Figures, Alzheimer s

More information

Dementia DR UMAR BEDI CONSULTANT-OLD AGE PSYCHIATRY 10/1/2018 1

Dementia DR UMAR BEDI CONSULTANT-OLD AGE PSYCHIATRY 10/1/2018 1 Dementia DR UMAR BEDI CONSULTANT-OLD AGE PSYCHIATRY 10/1/2018 1 TOPICS FOR DISCUSSION Man- FETCH Wife- THE DOG DIED 2 YEARS AGO HENRY 10/1/2018 2 TOPICS FOR DISCUSSION Dementia news What is Dementia? Why

More information

Clinical Trials: Questions and Answers

Clinical Trials: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Clinical Trials: Questions

More information

PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS BACKGROUND Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease (MND) is

More information

National Survivorship and QoL Research:

National Survivorship and QoL Research: National Survivorship and QoL Research: Impact on Interventions, Guidelines, and Resources Kevin D. Stein, PhD, Vice President, Behavioral Research, Director, Behavioral Research Center, American Cancer

More information